glp 1 addiction trials GLP-1s Like Ozempic May Be a New Treatment for GLP-1 Genetics: How Genes Affect

Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms

Lancet Diabetes Endocrinol (2019) 7(10):77685

113115 GLP-1RAs, which are associated with a reduction in lean muscle mass as well as adipose tissue loss, 116 may therefore put patients with IBD at a greater risk of sarcopenia, and prospective data are needed to further investigate

A Quick Overview of GLP-1 Medicines GLP-1 medicines mimic the hormone glucagon-like peptide-1, released by your intestines

Abbreviations EMA: European Medicines Agency FDA: Food and Drug Administration GIP: Glucose-dependent insulinotropic peptide GLP-1 RA: Glucagon-like peptide-1 receptor agonist MACE: Major adverse cardiovascular events References Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease

You'll know exactly what's happening inside your body before we prescribe anything